Correction to:
Wien Klin Wochenschr 2018
10.1007/s00508-018-1381-5
Unfortunately, the original version of this article contained two mistakes.
The text passage “It should be mentioned here that in the case of apixaban, dose adjustment is not based on GFR. A lower dosage of apixaban should be used if serum creatinine is ≥1.5 mg/dl (133 µmol/l) and either one of the following criteria is fulfilled: age ≥80 years or weight ≤60 kg.” is incorrect because GFR alone is a dose reduction criterion for apixaban in patients with NVAF if it falls below 30 ml/min.
In addition the sentence “There are specific recommendations for dose reduction of dabigatran and apixaban1 in patients ≥80 years, but not for rivaroxaban and edoxaban” is incorrect. The correct sentence should be “There are specific recommendations for dose reduction of dabigatran and—only in NVAF—apixaban in patients ≥80 years, but not for rivaroxaban and edoxaban.”
We apologize for the mistakes.
Contributor Information
Thomas Gremmel, Phone: +43-1-40400-46700, Email: thomas.gremmel@meduniwien.ac.at.
Alexander Niessner, Phone: +43-1-40400-46140, Email: alexander.niessner@meduniwien.ac.at.
Ingrid Pabinger, Phone: +43-1-40400-44100, Email: ingrid.pabinger@meduniwien.ac.at.